Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock
The company has tremendous prospects.
Goldman Sachs has added Vertex Pharmaceuticals to its list of highest conviction stocks, giving the biotech a buy rating and a price target of $653 per share. Although analysts are divided on Vertex, the bank's bullish stance suggests confidence in the company's prospects. Vertex focuses on developing innovative medicines for diseases with significant unmet medical needs, often targeting rare conditions.
This approach has both benefits and drawbacks. While the company's addressable market in some areas might be limited, it also faces less competition compared to larger, more competitive markets. Most of Vertex's revenue currently comes from its cystic fibrosis treatments, which address a rare disease causing thick mucus buildup in the lungs, leading to breathing difficulties, infections, and chronic issues.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
